James Rolke - Revelation Biosciences CEO Director
| REVB Stock | USD 1.65 0.18 12.24% |
Insider
James Rolke is CEO Director of Revelation Biosciences
| Age | 57 |
| Address | 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 650 800 3717 |
| Web | https://www.revbiosciences.com |
James Rolke Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Rolke against Revelation Biosciences stock is an integral part of due diligence when investing in Revelation Biosciences. James Rolke insider activity provides valuable insight into whether Revelation Biosciences is net buyers or sellers over its current business cycle. Note, Revelation Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revelation Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Rolke few days ago Disposition of 8521 shares by James Rolke of Revelation Biosciences at 1.86 subject to Rule 16b-3 | ||
James Rolke over a year ago Acquisition by James Rolke of 2542 shares of Revelation Biosciences subject to Rule 16b-3 |
Revelation Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5264) % which means that it has lost $0.5264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1888) %, meaning that it created substantial loss on money invested by shareholders. Revelation Biosciences' management efficiency ratios could be used to measure how well Revelation Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 9, 2026, Return On Tangible Assets is expected to decline to -2.74. The current year's Return On Capital Employed is expected to grow to -1.85. At present, Revelation Biosciences' Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 68 M, whereas Total Assets are forecasted to decline to about 5.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| HuiLan Wu | Ainos Inc | 63 | |
| Abi MD | BioLineRx | 47 | |
| LLB BSc | BioLineRx | N/A | |
| CPA CPA | Lipocine | 54 | |
| Liron MBA | BioLineRx | N/A | |
| CPA CPA | GeoVax Labs | 62 | |
| CPA MBA | BioLineRx | 62 | |
| Krista Fogarty | Lipocine | 58 | |
| John Esq | Ainos Inc | 57 | |
| Logan Morse | Lipocine | 56 | |
| McKee MD | GeoVax Labs | 72 | |
| Jael MSc | BioLineRx | N/A | |
| John Lacey | BioLineRx | N/A | |
| Mark Newman | GeoVax Labs | 71 | |
| Raziel Fried | BioLineRx | N/A | |
| Advocate Kotler | BioLineRx | 72 | |
| M MD | Lipocine | 66 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| CPA CPA | BioLineRx | 49 | |
Management Performance
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 |
Revelation Biosciences Leadership Team
Elected by the shareholders, the Revelation Biosciences' board of directors comprises two types of representatives: Revelation Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revelation. The board's role is to monitor Revelation Biosciences' management team and ensure that shareholders' interests are well served. Revelation Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revelation Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Rolke, CEO Director | ||
| Carol Odle, Director Projects | ||
| Chester III, Chief Officer | ||
| Sandra Vedrick, Vice Relations |
Revelation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revelation Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (8.38 M) | ||||
| Shares Outstanding | 2.62 M | ||||
| Shares Owned By Insiders | 23.70 % | ||||
| Shares Owned By Institutions | 18.20 % | ||||
| Number Of Shares Shorted | 27.31 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.39 X | ||||
| Price To Sales | 2.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. Anticipated expansion of Revelation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Revelation Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Revelation Biosciences requires distinguishing between market price and book value, where the latter reflects Revelation's accounting equity. The concept of intrinsic value - what Revelation Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Revelation Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Revelation Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Revelation Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Revelation Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.